Skip to main content

How to prepare: Radiation Oncology Model, Part 1

Check your participation status and build your plan

Are you a hospital outpatient department, physician group practice or freestanding clinic providing radiation therapy services? If so, you may be required to adopt the new mandatory Radiation Oncology Model.

Mandatory participation is randomized by Core-based Statistical Areas. You can check your organization’s participation status online. CMS released the Final Rule for the RO Model, giving providers 60 days to prepare for program launch on January 1, 2022. If your organization performs radiation therapy in a ZIP code on the list, you will need to begin preparing for the model.

Build your team

For effective planning, your practice should first identify a governance team to lead transition planning. This team should be multidisciplinary to assist with the different components of the RO Model. Team members should include:
  • Administrative Leaders
  • Physician Leaders
  • Finance
  • Quality
  • Information Technology
  • Population Health

Learn the rules

It is imperative for your working team to understand the RO Model requirements, including new billing guidelines, quality measures and clinical data reporting requirements. In accordance to the Final Rule, the requirement that RO participants collect and subject quality measures and clinical data elements will be optional in PY1 2022.

Unlike the fee-for-service model, the RO Model is a two-part prospective payment model with new billing codes and modifiers used to indicate the start and end of an approved radiation therapy episode. Included cancer types and modalities of treatment are listed on the CMS website.

RO Model quality measures and clinical data element reporting requirements will require your practice to adapt and work collaboratively to enable practice transformation efforts and ensure accurate documentation and accessible reports.

Your team may need to adjust your practice workflow to ease data abstraction for analysis and reporting.

Leverage expertise

Practices should consider partnering with a third-party resource to understand their data in the context of the RO Model in preparation for implementation. As there are many factors that impact CMS reconciliation, providers should look for partners who specialize in claims data analysis, data analytics and payment monitoring.

DataGen offers payment policy expertise and value-based strategies that help providers effectively navigate healthcare payment changes like the RO Model. Working closely with organizations, DataGen:
  • reviews practice claims data to ensure compliance with the model;
  • validates that CMS applied the methodology as described in the rules for accurate reconciliation results;
  • helps practices understand trends in their data that are influencing their performance; and
  • evaluates the impact of future program changes for providers and help them plan and prepare for what’s next.
Stay tuned for more details on How to Prepare: Part 2 – Billing Guidelines.


Popular posts from this blog

BPCI Advanced – take advantage of the model extension now

The Bundled Payment for Care Improvement (BPCI) Advanced Model is now open for applications until May 31, 2023. This model provides a unique opportunity to acute care hospitals and physician group practices who are looking to: evaluate their bundle performance; rejoin if they have previously dropped out due to being under a convener; or take advantage of the changes to the model. With a small window to sign the participation agreement, you’ll need experts to process data quickly and accurately for evaluation. BPCI Advanced Program Details The Centers for Medicare & Medicaid Services (CMS) announced in October 2022 that this program will extend from January 2024 to December 2025. Data used for evaluation will be taken from the baseline period between October 2018 and September 2022. A participation agreement will be sent out in September 2023 and needs to be signed by October 2023 in order to participate. Those who apply before the May 31 deadline will benefit

BPCI Advanced Model Extension

CMS recently made several major announcements about the Bundled Payments for Care Improvement Advanced Model.  The model, which was due to expire at the end of 2023 (Model Year 6), will be extended for an additional two years through Dec. 31, 2025.  New applications will be accepted in 2023 for the two-year extension. Participants still active in Model Year 6 can continue without reapplying by signing an amended and restated participation agreement for Model Year 7.  New methodological changes will be implemented for Model Year 6, which starts on Jan. 1, 2023. Methodological changes include that: the CMS Discount Factor for medical clinical episodes will be reduced from 3% to 2%;  the Peer Group Trend Factor Adjustment cap for all clinical episodes will be reduced from 10% to 5%; the Major Joint Replacement of the Upper Extremity clinical episode category will become a multi-setting episode category by allowing episodes to be triggered when the procedure is performed in the hospital ou

You’ve been accepted to the Enhancing Oncology Model. Now what?

The Centers for Medicare and Medicaid Services Innovation Center recently announced approved applicants for the new Enhancing Oncology Model. If your facility has been selected by CMS, are you still weighing your options during the current baseline evaluation period?  Two deciding factors may include the program data that CMS provides and whether EOM is enough of an improvement over the prior Oncology Care Model to make your investment worthwhile. Another factor to consider: Will you have the resources in place to conduct a baseline evaluation before EOM’s program start on July 1, 2023? How EOM differs from OCM EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. It includes three major updates: Fewer cancer types. Compared with OCM’s 21, EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic le